NEW YORK (TheStreet) -- Baidu (BIDU) - Get Report stock is down by 6.99% to 180.72 on heavy trading volume this morning, as China's Internet regulator will investigate the Chinese search engine regarding the death of a university student, who used Baidu to search for a treatment for his cancer.

The student Wei Zexi's search on Baidu led him to a department within the Second Hospital of Beijing Armed Police that offered an experimental form of cancer treatment that failed, Reuters reports. The 21-year-old died last month.

Before his death, Wei accused Baidu of promoting false medical information.

China's Internet regulator, the health ministry and the State Administration for Industry and Commerce will investigate Baidu and publicize its conclusions, Reuters adds.

"Baidu strives to provide a safe and trustworthy search experience for our users, and have launched an immediate investigation of the matter," the company said in a statement, according to Reuters.

About 5.85 million shares of Baidu have been traded so far today, well above the company's average trading volume of roughly 2.25 million shares per day.

Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.

Baidu's strengths such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins outweigh the fact that the company has had lackluster performance in the stock itself.

You can view the full analysis from the report here: BIDU

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.